Ian..PFE..still holding?..
Another molecule they acquired..AG13736, also sounds quite strong..
<< which was acquired along with Warner-Lambert Co. in 2000. In a trial, AG13736 achieved a partial response -- at least a 30% reduction in tumor size -- in 46% of 52 patients with late-stage kidney cancer.
In a study with Sutent, the once-a-day pill proved effective in stanching growth of a rare stomach cancer called GIST (for gastrointestinal stromal tumor) in 385 patients who had developed resistance to the blockbuster cancer drug Gleevec from Novartis. In the randomized study, two-thirds of the patients got Sutent and the others got a placebo.
On average, said George Demetri, a researcher at Dana-Farber Cancer Institute in Boston who led the study, tumor growth was arrested for six months with Sutent, compared with six weeks on a placebo.[this is what I call clinical benefit]
"We really saw that the disease was stopped in its tracks by the drug," Dr. Demetri said. Moreover, by genetically analyzing the tumors, researchers determined that they could predict which patients were more likely to respond well to the drug. Instead of the "trial and error" approach that is common in choosing treatment for cancer patients, Dr. Demetri said, genetic data will enable "rational decision making.">>
Markers are here, are here to stay..
Zeta |
